Nurullah İlhan, Associate Professor of Medical Oncology at Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, shared on X:
“SANOVO
1L EGFR-mutant, MET-overexpressing advanced NSCLC. Savolitinib + osimertinib vs osimertinib: median PFS 24.9 vs 13.8 months (HR 0.56). Primary PFS met. Should MET testing move upfront?”
Discover more:
